Mirae Asset Global Etfs Holdings Ltd. Moon Lake Immunotherapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 15,456 shares of MLTX stock, worth $583,309. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,456
Previous 13,590
13.73%
Holding current value
$583,309
Previous $685,000
19.85%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding MLTX
# of Institutions
137Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$745 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$321 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$126 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$105 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$82.5 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.39B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...